Intestinal health benefits of bovine whey proteins after simulated gastrointestinal digestion

Intestinal health benefits of bovine whey proteins after simulated gastrointestinal digestion

Bovine whey proteins are widely incorporated in foods for their nutritional, health promoting and functional value. However, whey proteins are readily digested in the upper gut. The objective of this study was to determine the fate and bioactivity of bovine whey proteins post simulated gastrointesti...

Full description

Bibliographic Details
Main Authors:	Alberto R. Corrochano, Elena Arranz, Ivano De Noni, Milda Stuknytė, Anita Ferraretto, Phil M. Kelly, Vitaly Buckin, Linda Giblin
Format:	Article
Language:	English
Published:	Elsevier 2018-10-01
Series:	Journal of Functional Foods
Subjects:	Whey protein In vitro digestion Bioactive peptide Glucagon-like peptide-1 Dipeptidyl peptidase IV inhibitor Antioxidant activity
Online Access:	http://www.sciencedirect.com/science/article/pii/S1756464618304754

Similar Items

Lechenie sakharnogo diabeta 2 tipa ingibitorami dipeptidilpeptidazy-4
Published: (2010-09-01)

Pathogenetic substantiation and effectiveness of vildagliptin use inpatients with diabetes mellitus type 2
Published: (2009-09-01)

Dipeptidyl Peptidase (DPP)-IV Inhibitors with Antioxidant Potential Isolated from Natural Sources: A Novel Approach for the Management of Diabetes
by: Anand-Krishna Singh, et al.
Published: (2021-06-01)

Dipeptidyl Peptidase IV Inhibitory Peptides Generated in Dry-Cured Pork Loin during Aging and Gastrointestinal Digestion
by: Paulina Kęska, et al.
Published: (2022-02-01)

Do whey protein-derived peptides have dual dipeptidyl-peptidase IV and angiotensin I-converting enzyme inhibitory activities?
by: Isabelle M.E. Lacroix, et al.
Published: (2016-03-01)

Identification and dipeptidyl peptidase IV (DPP-IV) inhibitory activity verification of peptides from mouse lymphocytes
by: Juan Wang, et al.
Published: (2022-11-01)

Endogenous GLP-1 levels play an important role in determining the efficacy of DPP-IV Inhibitors in both prediabetes and type 2 diabetes
by: Shiau Chin Chong, et al.
Published: (2022-10-01)

Effects of Incretin-Based Therapies on Diabetic Microvascular Complications
by: Yu Mi Kang, et al.
Published: (2017-09-01)

Exploring the DPP-IV Inhibitory, Antioxidant and Antibacterial Potential of Ovine “Scotta” Hydrolysates
by: Roberto Cabizza, et al.
Published: (2021-12-01)

Clinical and Physiological Characterization of Elevated Plasma Glucagon-Like Peptide-1 Levels (Hyperglipemia) in a Dipeptidyl Peptidase IV Mutation Carrier
by: Dandan Zhao, et al.
Published: (2018-03-01)

Effects of Thiazolidinedione and New Antidiabetic Agents on Stroke
by: Chang Ho Ahn, et al.
Published: (2019-05-01)

Bioactive Peptides as Potential Nutraceuticals for Diabetes Therapy: A Comprehensive Review
by: Priya Antony, et al.
Published: (2021-08-01)

Comparative effects of incretin-based therapy on doxorubicin-induced nephrotoxicity in rats: the role of SIRT1/Nrf2/NF-κB/TNF-α signaling pathways
by: Sandy R. Botros, et al.
Published: (2024-02-01)

The high need for trials assessing functional outcome after stroke rather than stroke prevention with GLP-1 agonists and DPP-4 inhibitors
by: Vladimer Darsalia, et al.
Published: (2018-02-01)

Influence of Diet and Gender on Plasma DPP4 Activity and GLP-1 in Patients with Metabolic Syndrome: An Experimental Pilot Study
by: Francisco Tomás Pérez-Durillo, et al.
Published: (2018-06-01)

Dipeptidyl Peptidase-IV Inhibitory Activity and Related Molecular Mechanism of Bovine α-Lactalbumin-Derived Peptides
by: Jing Gao, et al.
Published: (2020-06-01)

Dipeptidyl peptidase IV and its implication in cancer
by: Yarini M Arrebola, et al.

Discovery and functional mechanism of novel dipeptidyl peptidase Ⅳ inhibitory peptides from Chinese traditional fermented fish (Chouguiyu)
by: Daqiao Yang, et al.
Published: (2022-01-01)

Physiology and Pharmacology of DPP-4 in Glucose Homeostasis and the Treatment of Type 2 Diabetes
by: Carolyn F. Deacon
Published: (2019-02-01)

Corrigendum: Physiology and Pharmacology of DPP-4 in Glucose Homeostasis and the Treatment of Type 2 Diabetes
by: Carolyn F. Deacon
Published: (2019-05-01)

Quassia amara bioactive compounds as a Novel DPP-IV inhibitor: an in-silico study
by: Ezekiel A. Olugbogi, et al.
Published: (2022-07-01)

Acute and Chronic Exposure to Linagliptin, a Selective Inhibitor of Dipeptidyl Peptidase-4 (DPP-4), Has an Effect on Dopamine, Serotonin and Noradrenaline Level in the Striatum and Hippocampus of Rats
by: Małgorzata Łupina, et al.
Published: (2024-03-01)

Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin
by: Ahren B
Published: (2010-03-01)

Vildagliptin, a dipeptidyl peptidase-4 inhibitor, attenuated endothelial dysfunction through miRNAs in diabetic rats
by: Qian Zhang, et al.
Published: (2019-07-01)

Role of Incretin Axis in Inflammatory Bowel Disease
by: Lihua Duan, et al.
Published: (2017-12-01)

Las incretinas como nueva opción terapéutica en la diabetes mellitus tipo 2
by: Félix Andrés Reyes Sanamé, et al.

Association Between Diabetes Medications and the Risk of Parkinson's Disease: A Systematic Review and Meta-Analysis
by: Xiaocui Qin, et al.
Published: (2021-07-01)

Receptor-Mediated Bioassay Reflects Dynamic Change of Glucose-Dependent Insulinotropic Polypeptide by Dipeptidyl Peptidase 4 Inhibitor Treatment in Subjects With Type 2 Diabetes
by: Tsuyoshi Yanagimachi, et al.
Published: (2020-04-01)

Protein Digestion-Derived Peptides and the Peripheral Regulation of Food Intake
by: Benoit Cudennec, et al.
Published: (2017-04-01)

Glucagon-like peptide 1 receptor agonists and thyroid cancer: is it the time to be concerned?
by: Giuseppe Lisco, et al.
Published: (2023-10-01)

Bioactivities of hemorphins released from bovine haemoglobin gastrointestinal digestion: Dual effects on intestinal hormones and DPP-IV regulations
by: Dorothée Domenger, et al.
Published: (2017-09-01)

Incretin-based therapy: renal effects
by: Anton Ivanovich Korbut, et al.
Published: (2016-01-01)

Incretins as a Potential Treatment Option for Gestational Diabetes Mellitus
by: Aleksandra Pilszyk, et al.
Published: (2022-09-01)

Patterns and trends of utilization of incretin-based medicines between 2008 and 2014 in three Italian geographic areas
by: Giuseppe Roberto, et al.
Published: (2019-02-01)

Long-Acting Glucagon-Like Peptide-1 Receptor Agonists Suppress Voluntary Alcohol Intake in Male Wistar Rats
by: Vincent N. Marty, et al.
Published: (2020-12-01)

Functional foods with dipeptidyl peptidase‐4 inhibitory potential and management of type 2 diabetes: A review
by: Mutiu Kazeem, et al.
Published: (2021-06-01)

Gastrointestinal Incretins—Glucose-Dependent Insulinotropic Polypeptide (GIP) and Glucagon-like Peptide-1 (GLP-1) beyond Pleiotropic Physiological Effects Are Involved in Pathophysiology of Atherosclerosis and Coronary Artery Disease—State of the Art
by: Szymon Jonik, et al.
Published: (2022-02-01)

Fast Skeletal Muscle Troponin and Tropomyosin as a Dietary Source of Antidiabetic and Antihypertensive Bioactive Peptides: An In Silico Study
by: Jorge Andrés Barrero, et al.
Published: (2023-02-01)

Strong Association between Plasma Dipeptidyl Peptidase-4 Activity and Impaired Cognitive Function in Elderly Population with Normal Glucose Tolerance
by: Bo Chen, et al.
Published: (2017-07-01)

Glucagon like Peptide-1(GLP-1) a Novel Therapeutic Strategy in Non-Alcoholic Fatty Liver Disease (NAFLD)
by: Ebrahim Abbasi Oshaghi
Published: (2017-12-01)